Adalimumab: a new modality for Behçet's disease? - Wikidata - wikimedia - TriplyDB

Adalimumab: a new modality for Behçet's disease?

Adalimumab: a new modality for Behçet's disease?

http://www.wikidata.org/entity/Q42844975

about

Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease Adalimumab in the management of Behçet's disease Gastrointestinal Behçet's disease: a review Behçet's Uveitis.Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.Treatment of neuro-Behçet's disease: an update.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.Adalimumab in dermatology Managing Behçet's disease: An update on current and emerging treatment options.Adalimumab for Ocular Inflammation.Update on the Medical Management of Gastrointestinal Behçet's Disease.Emerging biologics in the treatment of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Biologics in oral medicine: ulcerative disorders.Adalimumab for the treatment of Behçet's disease: experience in 19 patients.Cytokines in the colon of a patient with Behçet's disease.Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab.Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease?Biologic therapy in primary systemic vasculitis of the young.Chronic signs of memory B cell activation in patients with Behçet's disease are partially restored by anti-tumour necrosis factor treatment.Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease Anakinra treatment in drug-resistant Behcet’s disease: a case series

P2860

Q26775240-A233DA9C-E147-47E2-B227-966A1B0E5A0D Q26777598-ED591807-A170-497D-AA60-042CA216795C Q26861428-AC0A0569-234B-4097-B6D8-3235CB975AA1 Q28084556-1A2AD424-CB54-4C75-81B0-CA5216E6D718 Q33559788-37AC94D7-3937-4D71-955E-E458D247F274 Q34142185-1294B2F0-0843-42D5-BCB2-B637491879B8 Q34974052-6F55D0CF-8314-4202-9B34-B2172402735B Q36171750-97B82840-C675-4D1C-9715-16C801982EAC Q37105146-C6108F43-53C1-4E3A-A780-6127F65E0D89 Q37118888-82CE97B0-8319-47F2-A58F-F788D0E09290 Q37142425-75B8C8EF-3044-4334-B1A6-AC2802667552 Q37230348-37947482-1200-4CBE-8AD6-35F83E89785B Q37276953-7C815A3C-1F2D-47F9-A46A-AEB9B04A9B6D Q37624811-F4B0C996-8BAE-49A4-89BB-E558F3B08114 Q37754665-F2E313D9-578A-49AE-AADA-28BD4A1BC2A1 Q37756167-B5331109-50F1-407C-B4E5-554E9033EDD7 Q37999475-0EBB9921-B566-41E8-A04B-5357502BEE79 Q38020828-67504FCF-ADDA-46DB-A6EF-E52E9ED67C7B Q41967179-B3A8273F-9142-4FC2-8129-E229667DCC1A Q43016617-EB8A8AAE-130B-4805-8626-A1AF41AADF08 Q43120868-8469FC47-D2E4-4090-8CAA-E7C97F932DC5 Q45964920-30AC6DF1-815A-4DD1-A903-89F24972A210 Q50620297-00FDBB56-61E3-47FF-A90C-E6AB1EB39044 Q51794535-EE2DA1A2-9323-4BBF-9EE7-8BC68507C1BA Q56974494-AFEDD352-3C01-4EC3-835F-3C3262180EEA Q57612968-A51FCA7A-F509-44B8-ABDA-4639DA1FB81D Q58326155-E82BFE0E-3CA1-4DA4-AEB3-F1576115E6A9

P2860

Adalimumab: a new modality for Behçet's disease?

http://www.wikidata.org/entity/Q42844975

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Adalimumab: a new modality for Behçet's disease?

@en

Adalimumab: a new modality for Behçet's disease?

@nl

type

label

Adalimumab: a new modality for Behçet's disease?

@en

Adalimumab: a new modality for Behçet's disease?

@nl

prefLabel

Adalimumab: a new modality for Behçet's disease?

@en

Adalimumab: a new modality for Behçet's disease?

@nl

P1433

Q42844975-C573E356-1990-44A8-AFEB-0842A0591C33

P1476

Q42844975-770A0398-6AB7-442F-AC5F-FADB825BAB02

P2093

Q42844975-5040CD20-2C24-4CFD-90C1-23FFDC7CF733

Q42844975-7DD1B426-FD37-4015-8025-F29AEB47E6C5

Q42844975-902C2637-B747-42C8-AA5D-D598FA11DC6E

Q42844975-B835C60C-624E-4040-8BFD-2AE1E92EA0BC

Q42844975-DDD79C00-5DD8-424B-8978-8198FCB8BD81

Q42844975-F45BB503-30E6-4EAD-ACB1-85DC581B72D3

P2860

Q42844975-6B47728D-2569-48FC-8A8E-FC431C03EC17

Q42844975-A0C725B3-5E87-479F-91A3-CBF070E9A9FE

Q42844975-A70DA60C-BD7A-4986-AAAA-83AC40E9FB77

Q42844975-AFE6C13D-333F-454B-9553-00D48D5886EC

Q42844975-B90247C8-15CE-4DCC-8968-A9C43BF5E2AF

Q42844975-C5AADAF9-378D-4F56-B010-5919F457BA3E

Q42844975-C6FC579F-302C-4EEA-8329-0A33F3F4A87F

Q42844975-CDAB507B-79AA-41B4-9AB8-E9F558079EE5

Q42844975-FE007541-90FA-4652-A3CE-E070329FE40B

P304

Q42844975-DAF8F70D-EB91-4FAF-8442-4B7E65C2C020

P31

Q42844975-8DEB593B-74D4-4A15-A252-7836B0A2AD82

P356

Q42844975-8A4FE325-2170-4F86-8F74-0EC1216F8E70

P407

Q42844975-6FB0319D-89C8-4BD3-803F-A6B488C64F4E

P433

Q42844975-58C1A303-892A-4DB9-9228-71AA8D013946

P478

Q42844975-34FBA5EA-1AA8-4C94-8D35-0A28D3DA2AA3

P577

Q42844975-53472E9A-1CF3-41C4-851F-666A90BD63B9

P5875

Q42844975-9430E8D8-0BEE-4080-8B0B-729F871CB1A6

P698

Q42844975-51625BC1-EAAB-42A3-873A-AD03A004CB2C

P921

Q42844975-14DBA7F2-C23C-4C84-A4A4-8F4EC1B66E6D

Q42844975-A3F6052E-8C88-44FD-8654-4EE9E078C8CB

P932

Q42844975-923CB6E5-68F2-43F7-9BD3-12DBE97E9560

P356

ARD.2006.064279

P1433

Annals of the Rheumatic Diseases

P1476

Adalimumab: a new modality for Behçet's disease?

@en

P2093

A Jamnitski

http://www.w3.org/2001/XMLSchema#string

G S Baarsma

http://www.w3.org/2001/XMLSchema#string

J A M van Laar

http://www.w3.org/2001/XMLSchema#string

P L A van Daele

http://www.w3.org/2001/XMLSchema#string

P M van Hagen

http://www.w3.org/2001/XMLSchema#string

T Missotten

http://www.w3.org/2001/XMLSchema#string

P2860

Behçet's disease.

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.

Anti-TNF-alpha therapy for sight threatening uveitis.

Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Current concepts in the etiology and treatment of Behçet disease.

[Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication]

Vgamma9Vdelta2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens.

P304

565-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2006.064279

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6674457

http://www.w3.org/2001/XMLSchema#string

P698

17124248

http://www.w3.org/2001/XMLSchema#string

P921

Behcet's disease

P932

1856047

http://www.w3.org/2001/XMLSchema#string